Royalty Pharma Increases Bid for Elan

NEW YORK (AP) -- Royalty Pharma is raising its offer to buy Elan (UNKNOWN: ELN.DL2  ) on the condition that shareholders reject the Irish drugmaker's push to refocus its business through a string of recently announced deals.

Royalty says it will pay $12.50 in cash for each share of Elan Corp. PLC. That adds up to a total value of about $7.5 billion.

Royalty offered in February to buy Elan for $11 per share and later raised that bid to $11.25 per share. Elan has said the $11.25 bid was much too low and said today that it would take the latest offer under review.

Royalty is a privately held New York company that buys royalty interests in drugs and late-stage drug candidates.

Elan plans to spend $1 billion for royalties from some respiratory treatments. It also plans to buy a privately held drugmaker and stakes in two others.

link


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2441809, ~/Articles/ArticleHandler.aspx, 7/30/2014 1:42:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement